Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Maybe eroxon could help Viagra work better
Just watched the interview and Barder is certainly upbeat. Now understand what he means by 20% incremental increase, I.e. Eroxon is not taking market share from other ED treatments, but rather expanding the overall market. Forward projections don’t even take into account US sales, futura looks bright. It’s a waiting game.
On a slightly tangential point re manufacturing,the inference i draw from borders webcast with proactive today,is that the current/pre_existing capacity is not adequate, hence the second manufacturer now appointed,and the clear reference to a third being required in due course.i assume the new one will need to satisfy quality requirements etc,so may be a little while before it is in actual production,but clearly fum are focussed on ensuring that the manufacturing capability will be up to scratch asap.
1.7m revenue with 0.9m profit, so I’m guessing this is the manufacturing costs, so around 16% profit still pretty good & those manufacturing costs will come down with scale.
So 200k units at £25 that’s £5m, I take that’s upto end of June 1.7m revenue from Eroxon then that 34% share of revenue???? Is this correct by everyone else’s calculations? Pretty good way above the 10%
Absolutely this is getting bought out all day long. 24/25 predictions an irrelevance in my eyes.
We need a whale, let’s hope it’s a blue one!
I suspect the product will be brought off Futura before they get it fully out to market. This product is game changing for the ed market and could fully replace viagra so I'm sure lots of big players are watching to see how it gets on.
Was just about to post it you beat me to it lol
Apologies. Should read 23/24 Yr going fwd
The $4m is actually £3.2. It was credited after this yrs results. So cant be included in this yrs only next yrs. But it is in Futuras bank now and is real. So my understanding is basically for 24/25 Yr we have an income(credit) in the Co for next yrs results of £3.2 m already before any further sales ( net income,milestones) that will be get credited less expenditures over 24/25.
If I was reporting upto last night and received £1m payment today it wouldn't get into accounts repor t until next yrs but would be in my bank though.
Thanks man. Lol wished i put a bet on that, felt would be between 100-200k units cos of the soft launch and it being only a few months to the period cut off.
I've just listened to the interview that's been released they have sold 200k units. They hope to break even in 2024 and make profit in 2025
Dont know. Great report! Would like actual sales units to see if m8ey on here was right with 1.2m units sold. They almost broke even! Awesome. Futura did say they would be a profitable company very soon. But why mention the 4m from haleon, wasnt that got after the june cut off, mentioning cash balance as of aug defo is... and 2.4 odd million already gone in 2 months? On what? Dont know as guess will be elaborated in next financials, why mention that aug cash balance now. Is that cause for the sp dip? Could just be me over thinking after 4hrs sleep feom watching NFL night. Any one elses thoughts or corrections for me?
Then up we go.
That`s close to 100% upside as you can get. Great entry level. Haleon plc to take us over at £2.00 is a real possibility.
And last weeks buyers ( hence tree shake effect ) pre results looking for a quick buck are exiting this morning. Get rid and its back on its trajectory.
Read between the lines. As per previous research. A lot of the 20% is basically in a new audience/additional consumer base. Any competitor customer gain is a bonus.
Reviews are addressed/explained in this video
Fireside Chat with James Barder, CEO of Futura Medical July 2023
https://futuramedical.com/investor-centre/videos-and-webcasts/videos/
I heard this differently: Eroxon® expected to gain around a 20% share of the clinically proven ED treatment market.
Watch the video again and tell me if I'm wrong please.. I heard and understood an incremental 20%. Read a new market on top of traditional ED. The cherry on the cake if you will.
Double bonus.
On current sales The total Reviews on boots represent 0.09% of units sold ( rough estimate ) of which majority negative yes …..But As has been stipulated the wording many reviews has been suspicious as has been the multiple upticking of negative reviews and downticking of positive reviews
Amazon reviews maybe 1.8% of total units sold
If you had high expectations for this product and it didn’t work well you would be pretty miffed and would be more likely to leave a review
A great update I thought. Cant believe price reaction. Bought another 22000 shares or so.
Think about it
If they are grabbing a 20% market share the viagra and Cialis markers stand to lose massively
It is clearly a dirty tricks campaign that has been orchestrated by short sellers and possibly the market leaders
Read what they write its always the same theme
Key things said:
Eroxon® sales to date have exceeded targets
Eroxon® expected to gain around a 20% share of the clinically proven ED treatment market
Key things left unsaid:
Projections on what revenue can be expected from 20% of these markets as we rollout the dozen or so countries in next 6 months.